Anna Ahn, MD
Internal Medicine · Stony Brook, NYNPI 1700105533
Payments from drug & device makers
Across 208 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$720
- GSK$606
- Boehringer Ingelheim$300
- Sanofi-aventis U.S. LLC$279
- Sanofi$248
- Harmony Biosciences LLC$221
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,59691%
- Education$3419%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $720 |
| GSK | 51 | $606 |
| Boehringer Ingelheim | 14 | $300 |
| Sanofi-aventis U.S. LLC | 3 | $279 |
| Sanofi | 14 | $248 |
| Harmony Biosciences LLC | 6 | $221 |
| Mylan Specialty L.p. | 9 | $187 |
| Insmed, Inc. | 9 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Mallinckrodt Hospital Products Inc. | 3 | $94 |
| United Therapeutics Corporation | 4 | $74 |
| Baxter Healthcare | 3 | $73 |
| Novartis | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Grifols USA, LLC | 4 | $66 |
| Amgen | 4 | $62 |
| Fisher & Paykel Healthcare Inc | 4 | $61 |
| Electromed, Inc. | 3 | $55 |
| Genentech USA, Inc. | 3 | $55 |
| Johnson & Johnson | 3 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $53 |
| Bayer | 2 | $44 |
| Merck | 2 | $41 |
| Philips North America LLC | 2 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 2 | $26 |
| Verona Pharma, Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
How this compares
$3,937 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 533 | $399,481 |
| Dupixent PenDupilumab | 57 | $234,140 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 222 | $158,859 |
| NucalaMepolizumab | 20 | $73,683 |
| Dupixent SyringeDupilumab | 19 | $73,250 |
| Breo ElliptaFluticasone/Vilanterol | 154 | $70,463 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $43,973 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $34,538 |
| Spiriva RespimatTiotropium Bromide | 43 | $32,663 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $17,344 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $16,135 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 432 | $15,947 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $12,577 |
| Arnuity ElliptaFluticasone Furoate | 54 | $12,218 |
| EliquisApixaban | 13 | $11,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $606 | $617,162883 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $720 | $179,848278 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $300 | $67,200101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Stony Brook
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.